Trial Outcomes & Findings for Inhaled Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Hereditary Pulmonary Alveolar Proteinosis (PAP) (NCT NCT01511068)
NCT ID: NCT01511068
Last Updated: 2023-08-30
Results Overview
A modified Bruce protocol stress test was used to evaluate improvement in blood oxygen saturation (SpO2). A pulse-oximeter was placed on the participant's finger with the participant at rest while sitting in a chair. Leads for the electrocardiograph were placed on the chest wall. The treadmill was started at 1.7 miles per hour (mph) and a grade of 0%. At three minute intervals, the speed increased as follows: 1.7 mph, 1.7 mph, 1.7 mph, 2.5 mph, 3.4 mph, 4.2 mph, 5.0 mph, 5.5 mph, 6.0 mph, 6.5 mph, 7.0 mph, and 7.5 mph. The participant stopped the test due to intolerable dyspnea or if the SpO2 fell below 88%.
COMPLETED
PHASE2
2 participants
Baseline, 7 months
2023-08-30
Participant Flow
Participant milestones
| Measure |
Inhaled Leukine (rhGM-CSF)
Inhaled recombinant human GM-CSF in individuals with Hereditary Pulmonary Alveolar Proteinosis (hPAP) due to partial dysfunction of the GM-CSF receptor
Leukine: Participants will receive inhaled rhGM-CSF (Sargramostim, Leukine) at the dose of 250 mcg one time per week for 12 weeks. Following an interim safety evaluation, participants may be entered into a second 12 week treatment period where participants will receive either 250 mcg or 500 mcg once weekly. At the end of any treatment period, participants will be followed for 12 additional weeks in the absence of inhaled rhGM-CSF to evaluate safety and efficacy.
|
|---|---|
|
Overall Study
STARTED
|
2
|
|
Overall Study
COMPLETED
|
2
|
|
Overall Study
NOT COMPLETED
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Inhaled Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Hereditary Pulmonary Alveolar Proteinosis (PAP)
Baseline characteristics by cohort
| Measure |
Inhaled Leukine (rhGM-CSF)
n=2 Participants
Inhaled recombinant human GM-CSF in individuals with Hereditary Pulmonary Alveolar Proteinosis (hPAP) due to partial dysfunction of the GM-CSF receptor
Leukine: Participants will receive inhaled rhGM-CSF (Sargramostim, Leukine) at the dose of 250 mcg one time per week for 12 weeks. Following an interim safety evaluation, participants may be entered into a second 12 week treatment period where participants will receive either 250 mcg or 500 mcg once weekly. At the end of any treatment period, participants will be followed for 12 additional weeks in the absence of inhaled rhGM-CSF to evaluate safety and efficacy.
|
|---|---|
|
Age, Categorical
<=18 years
|
2 Participants
n=99 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
0 Participants
n=99 Participants
|
|
Age, Categorical
>=65 years
|
0 Participants
n=99 Participants
|
|
Sex: Female, Male
Female
|
2 Participants
n=99 Participants
|
|
Sex: Female, Male
Male
|
0 Participants
n=99 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=99 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
2 Participants
n=99 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=99 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=99 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=99 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=99 Participants
|
|
Race (NIH/OMB)
White
|
2 Participants
n=99 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=99 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
|
Region of Enrollment
United States
|
2 participants
n=99 Participants
|
PRIMARY outcome
Timeframe: Baseline, 7 monthsA modified Bruce protocol stress test was used to evaluate improvement in blood oxygen saturation (SpO2). A pulse-oximeter was placed on the participant's finger with the participant at rest while sitting in a chair. Leads for the electrocardiograph were placed on the chest wall. The treadmill was started at 1.7 miles per hour (mph) and a grade of 0%. At three minute intervals, the speed increased as follows: 1.7 mph, 1.7 mph, 1.7 mph, 2.5 mph, 3.4 mph, 4.2 mph, 5.0 mph, 5.5 mph, 6.0 mph, 6.5 mph, 7.0 mph, and 7.5 mph. The participant stopped the test due to intolerable dyspnea or if the SpO2 fell below 88%.
Outcome measures
| Measure |
Inhaled Leukine (rhGM-CSF)
n=2 Participants
Inhaled recombinant human GM-CSF in individuals with Hereditary Pulmonary Alveolar Proteinosis (hPAP) due to partial dysfunction of the GM-CSF receptor
Leukine: Participants will receive inhaled rhGM-CSF (Sargramostim, Leukine) at the dose of 250 mcg one time per week for 12 weeks. Following an interim safety evaluation, participants may be entered into a second 12 week treatment period where participants will receive either 250 mcg or 500 mcg once weekly. At the end of any treatment period, participants will be followed for 12 additional weeks in the absence of inhaled rhGM-CSF to evaluate safety and efficacy.
|
|---|---|
|
Change in Time (Minutes) to Discontinuation of Exercise During a Standardized Treadmill Exercise Test
Participant 1
|
17 Percent Change
|
|
Change in Time (Minutes) to Discontinuation of Exercise During a Standardized Treadmill Exercise Test
Participant 2
|
33 Percent Change
|
PRIMARY outcome
Timeframe: Baseline, 7 monthsA modified Bruce protocol stress test was used to evaluate improvement in blood oxygen saturation (SpO2). A pulse-oximeter was placed on the participant's finger with the participant at rest while sitting in a chair. Leads for the electrocardiograph were placed on the chest wall. The treadmill was started at 1.7 miles per hour (mph) and a grade of 0%. At three minute intervals, the speed increased as follows: 1.7 mph, 1.7 mph, 1.7 mph, 2.5 mph, 3.4 mph, 4.2 mph, 5.0 mph, 5.5 mph, 6.0 mph, 6.5 mph, 7.0 mph, and 7.5 mph. The participant stopped the test due to intolerable dyspnea or if the SpO2 fell below 88%.
Outcome measures
| Measure |
Inhaled Leukine (rhGM-CSF)
n=2 Participants
Inhaled recombinant human GM-CSF in individuals with Hereditary Pulmonary Alveolar Proteinosis (hPAP) due to partial dysfunction of the GM-CSF receptor
Leukine: Participants will receive inhaled rhGM-CSF (Sargramostim, Leukine) at the dose of 250 mcg one time per week for 12 weeks. Following an interim safety evaluation, participants may be entered into a second 12 week treatment period where participants will receive either 250 mcg or 500 mcg once weekly. At the end of any treatment period, participants will be followed for 12 additional weeks in the absence of inhaled rhGM-CSF to evaluate safety and efficacy.
|
|---|---|
|
Change in Minimum Pulse Oximetry During a Standardized Treadmill Exercise Test
Participant 1
|
0 Percent Change
|
|
Change in Minimum Pulse Oximetry During a Standardized Treadmill Exercise Test
Participant 2
|
-2.1 Percent Change
|
SECONDARY outcome
Timeframe: Baseline, 7 monthsRoutine full pulmonary function testing, including spirometry, lung volumes, and DLCO, were performed according to American Thoracic Society guidelines.
Outcome measures
| Measure |
Inhaled Leukine (rhGM-CSF)
n=2 Participants
Inhaled recombinant human GM-CSF in individuals with Hereditary Pulmonary Alveolar Proteinosis (hPAP) due to partial dysfunction of the GM-CSF receptor
Leukine: Participants will receive inhaled rhGM-CSF (Sargramostim, Leukine) at the dose of 250 mcg one time per week for 12 weeks. Following an interim safety evaluation, participants may be entered into a second 12 week treatment period where participants will receive either 250 mcg or 500 mcg once weekly. At the end of any treatment period, participants will be followed for 12 additional weeks in the absence of inhaled rhGM-CSF to evaluate safety and efficacy.
|
|---|---|
|
Change in Diffusion Capacity for Carbon Monoxide
Participant 1
|
11 Percent Change
|
|
Change in Diffusion Capacity for Carbon Monoxide
Participant 2
|
4 Percent Change
|
SECONDARY outcome
Timeframe: Baseline, 7 monthsStandardized exercise pulse oximetry (SEPO) was used to measure SpO2 at the participant's home on a weekly basis between clinic visits. Briefly, a pulse-oximeter was placed on the finger with the participant at rest sitting in a chair. Three baseline (resting) readings were taken over a period of 1 minute to measure the SpO2 at rest. The participant then began stepping onto and off of the first step of a staircase in the home while holding onto the handrail for safety. Stepping was started by placing the bottom of one foot onto the stair followed by the other foot and then removal of one foot from the stair to the floor followed by the other foot. This procedure was repeated at a frequency of 1 cycle per second for a total of 5 minutes. The participant's parent assisted by noting the saturation data at 1-minute intervals during the test onto the weekly exercise form in the participant's Diary. The participant's saturation data continued to be recorded for 3 minutes after the test.
Outcome measures
| Measure |
Inhaled Leukine (rhGM-CSF)
n=2 Participants
Inhaled recombinant human GM-CSF in individuals with Hereditary Pulmonary Alveolar Proteinosis (hPAP) due to partial dysfunction of the GM-CSF receptor
Leukine: Participants will receive inhaled rhGM-CSF (Sargramostim, Leukine) at the dose of 250 mcg one time per week for 12 weeks. Following an interim safety evaluation, participants may be entered into a second 12 week treatment period where participants will receive either 250 mcg or 500 mcg once weekly. At the end of any treatment period, participants will be followed for 12 additional weeks in the absence of inhaled rhGM-CSF to evaluate safety and efficacy.
|
|---|---|
|
Change in Minimum Pulse Oximetry During a Standardized Exercise Protocol Oximetry
Participant 1
|
0 Percent Change
|
|
Change in Minimum Pulse Oximetry During a Standardized Exercise Protocol Oximetry
Participant 2
|
50 Percent Change
|
SECONDARY outcome
Timeframe: Baseline, 7 monthsHigh resolution computed tomography (HRCT) scans were performed using an interval technique, a 1 mm slice was obtained every 20 mm. The slice series were placed so that images were obtained from the pulmonary apices to the lung bases with one of the images located at the level of the carina. The CT parameters were performed at full inspiration and required a lower dose than usual clinical CT scans; 1 mm slices at 20 mm intervals,120 kVp, 60 mAs, rotation time 0.5 second. Images were reconstructed with lung and soft tissue reconstruction kernels (B35F and B60F). The primary analysis was performed using the B60F kernel. Images were read and reported according to Radiology Department protocol. The raw data was recorded on a DVD and sent to CCHMC for centralized reading and lung attenuation analysis.
Outcome measures
| Measure |
Inhaled Leukine (rhGM-CSF)
n=2 Participants
Inhaled recombinant human GM-CSF in individuals with Hereditary Pulmonary Alveolar Proteinosis (hPAP) due to partial dysfunction of the GM-CSF receptor
Leukine: Participants will receive inhaled rhGM-CSF (Sargramostim, Leukine) at the dose of 250 mcg one time per week for 12 weeks. Following an interim safety evaluation, participants may be entered into a second 12 week treatment period where participants will receive either 250 mcg or 500 mcg once weekly. At the end of any treatment period, participants will be followed for 12 additional weeks in the absence of inhaled rhGM-CSF to evaluate safety and efficacy.
|
|---|---|
|
Change in Radiographic Evidence of PAP Lung Disease
Participant 1-Right Lung Baseline
|
-510 Hounsfield Units
|
|
Change in Radiographic Evidence of PAP Lung Disease
Participant 1- Right Lung End of Treatment
|
-579 Hounsfield Units
|
|
Change in Radiographic Evidence of PAP Lung Disease
Participant 1-Left Lung Baseline
|
-366 Hounsfield Units
|
|
Change in Radiographic Evidence of PAP Lung Disease
Participant 1-Left Lung End of Treatment
|
-441 Hounsfield Units
|
|
Change in Radiographic Evidence of PAP Lung Disease
Participant 2-Right Lung Baseline
|
-593 Hounsfield Units
|
|
Change in Radiographic Evidence of PAP Lung Disease
Participant 2-Right Lung End of Treatment
|
-675 Hounsfield Units
|
|
Change in Radiographic Evidence of PAP Lung Disease
Participant 2-Left Lung Baseline
|
-630 Hounsfield Units
|
|
Change in Radiographic Evidence of PAP Lung Disease
Participant 2-Left Lung End of Treatment
|
-726 Hounsfield Units
|
SECONDARY outcome
Timeframe: Baseline, 7 monthsThe PedsQL quality of life questionnaire is a modular approach to measure health-related quality of life in healthy children and those with acute and chronic health conditions. It is self-administered and completed in less than 5 minutes. It contains 23 items divided into 4 domains: physical functioning, emotional functioning, social functioning, and school functioning. To reverse score, transform the 0-4 scale items to 0-100 as follows: 0=100, 1=75, 2=50, 3=25, 4=0. Higher scores indicate a better Health-Related Quality of Life.To create the Psychosocial Health Summary Score, the mean is computed as the sum of the items over the number of items answered in the Emotional, Social, and School Functioning Scales. The Physical Health Summary Score is the same as the Physical Functioning Scale Score. To create the Total Scale Score, the mean is computed as the sum of all the items over the number of items answered on all the Scales.
Outcome measures
| Measure |
Inhaled Leukine (rhGM-CSF)
n=2 Participants
Inhaled recombinant human GM-CSF in individuals with Hereditary Pulmonary Alveolar Proteinosis (hPAP) due to partial dysfunction of the GM-CSF receptor
Leukine: Participants will receive inhaled rhGM-CSF (Sargramostim, Leukine) at the dose of 250 mcg one time per week for 12 weeks. Following an interim safety evaluation, participants may be entered into a second 12 week treatment period where participants will receive either 250 mcg or 500 mcg once weekly. At the end of any treatment period, participants will be followed for 12 additional weeks in the absence of inhaled rhGM-CSF to evaluate safety and efficacy.
|
|---|---|
|
Change in Quality of Life
Participant 1 -Total Score
|
10.7 Percent Change
|
|
Change in Quality of Life
Participant 1 - Physical Health Score
|
75 Percent Change
|
|
Change in Quality of Life
Participant 1 - Psychosocial Score
|
-5.2 Percent Change
|
|
Change in Quality of Life
Participant 1 - Parent Score
|
19.6 Percent Change
|
|
Change in Quality of Life
Participant 1 - Child Score
|
3.1 Percent Change
|
|
Change in Quality of Life
Participant 2 - Total Score
|
11.7 Percent Change
|
|
Change in Quality of Life
Participant 2 - Physical Health Score
|
7.4 Percent Change
|
|
Change in Quality of Life
Participant 2- Psychosocial Score
|
14.5 Percent Change
|
|
Change in Quality of Life
Participant 2 - Parent Score
|
5.6 Percent Change
|
|
Change in Quality of Life
Participant 2 - Child Score
|
18.2 Percent Change
|
SECONDARY outcome
Timeframe: Baseline, 7 monthsThe dyspnea visual analogue scales were used by the patient to record the level of dyspnea by a single mark on a linear scale. The dyspnea scale ranged from 0 to 10, with short of breath all the time equal to 0 and never short of breath equal to 10. A higher score indicated a better dyspnea score.
Outcome measures
| Measure |
Inhaled Leukine (rhGM-CSF)
n=2 Participants
Inhaled recombinant human GM-CSF in individuals with Hereditary Pulmonary Alveolar Proteinosis (hPAP) due to partial dysfunction of the GM-CSF receptor
Leukine: Participants will receive inhaled rhGM-CSF (Sargramostim, Leukine) at the dose of 250 mcg one time per week for 12 weeks. Following an interim safety evaluation, participants may be entered into a second 12 week treatment period where participants will receive either 250 mcg or 500 mcg once weekly. At the end of any treatment period, participants will be followed for 12 additional weeks in the absence of inhaled rhGM-CSF to evaluate safety and efficacy.
|
|---|---|
|
Change in Dyspnea Symptom Score
Participant 1
|
71 Percent Change
|
|
Change in Dyspnea Symptom Score
Participant 2
|
11 Percent Change
|
SECONDARY outcome
Timeframe: Baseline and monthly up to 7 monthsSerum GM-CSF autoantibody was measured as follows: microtiter plates were incubated (4°C, overnight) with rhGM-CSF, washed in PBS and Tween-20, and incubated (room temperature (RT), 1 hour) with blocking solution. Serum samples were diluted with dilution buffer and aliquots of diluted serum or standard were pipetted into adjacent microtiter wells, incubated at RT for 40 minutes, and then washed with wash buffer. Horseradish peroxidase-conjugated secondary antibody was diluted with dilution buffer and pipetted into each well. Plates were incubated (RT, 0.5 hour) and then washed with wash buffer. Substrate solution was added to each well, plates were incubated (RT, 15 min), and color development was stopped with sulfuric acid. Absorbance at 450 nm was measured using a Benchmark® ELISA plate reader.
Outcome measures
| Measure |
Inhaled Leukine (rhGM-CSF)
n=2 Participants
Inhaled recombinant human GM-CSF in individuals with Hereditary Pulmonary Alveolar Proteinosis (hPAP) due to partial dysfunction of the GM-CSF receptor
Leukine: Participants will receive inhaled rhGM-CSF (Sargramostim, Leukine) at the dose of 250 mcg one time per week for 12 weeks. Following an interim safety evaluation, participants may be entered into a second 12 week treatment period where participants will receive either 250 mcg or 500 mcg once weekly. At the end of any treatment period, participants will be followed for 12 additional weeks in the absence of inhaled rhGM-CSF to evaluate safety and efficacy.
|
|---|---|
|
Change in Serum Anti-GM-CSF Antibodies Levels
Participant 1-Visit 0-Baseline
|
0.67 micrograms/ml
|
|
Change in Serum Anti-GM-CSF Antibodies Levels
Participant 1-Visit 1-Begin Low Dose Therapy
|
0.36 micrograms/ml
|
|
Change in Serum Anti-GM-CSF Antibodies Levels
Participant 1-Visit 2
|
0.32 micrograms/ml
|
|
Change in Serum Anti-GM-CSF Antibodies Levels
Participant 1-Visit 3
|
1.85 micrograms/ml
|
|
Change in Serum Anti-GM-CSF Antibodies Levels
Participant 1-Visit 4
|
19.7 micrograms/ml
|
|
Change in Serum Anti-GM-CSF Antibodies Levels
Participant 1-Visit 5-Begin High Dose Therapy
|
71.8 micrograms/ml
|
|
Change in Serum Anti-GM-CSF Antibodies Levels
Participant 1-Visit 6
|
118.1 micrograms/ml
|
|
Change in Serum Anti-GM-CSF Antibodies Levels
Participant 1-Visit 7
|
128.2 micrograms/ml
|
|
Change in Serum Anti-GM-CSF Antibodies Levels
Participant 1-Visit 8 - End of Therapy
|
110.7 micrograms/ml
|
|
Change in Serum Anti-GM-CSF Antibodies Levels
Participant 2-Baseline
|
0.551 micrograms/ml
|
|
Change in Serum Anti-GM-CSF Antibodies Levels
Participant 2-Begin Therapy
|
0.358 micrograms/ml
|
|
Change in Serum Anti-GM-CSF Antibodies Levels
Participant 2-Visit 2
|
0.299 micrograms/ml
|
|
Change in Serum Anti-GM-CSF Antibodies Levels
Participant 2-Visit 3
|
81.04 micrograms/ml
|
|
Change in Serum Anti-GM-CSF Antibodies Levels
Participant 2-Visit 4
|
132.52 micrograms/ml
|
|
Change in Serum Anti-GM-CSF Antibodies Levels
Participant 2-Visit 5-Begin High Dose Therapy
|
123.66 micrograms/ml
|
|
Change in Serum Anti-GM-CSF Antibodies Levels
Participant 2-Visit 6
|
116.82 micrograms/ml
|
|
Change in Serum Anti-GM-CSF Antibodies Levels
Participant 2-Visit 7
|
104.36 micrograms/ml
|
|
Change in Serum Anti-GM-CSF Antibodies Levels
Participant 2-Visit 8 - End of Therapy
|
91.92 micrograms/ml
|
SECONDARY outcome
Timeframe: Baseline and monthly up to 7 monthsSerum GM-CSF was measured via a commercial ELISA kit from R \& D Systems.
Outcome measures
| Measure |
Inhaled Leukine (rhGM-CSF)
n=2 Participants
Inhaled recombinant human GM-CSF in individuals with Hereditary Pulmonary Alveolar Proteinosis (hPAP) due to partial dysfunction of the GM-CSF receptor
Leukine: Participants will receive inhaled rhGM-CSF (Sargramostim, Leukine) at the dose of 250 mcg one time per week for 12 weeks. Following an interim safety evaluation, participants may be entered into a second 12 week treatment period where participants will receive either 250 mcg or 500 mcg once weekly. At the end of any treatment period, participants will be followed for 12 additional weeks in the absence of inhaled rhGM-CSF to evaluate safety and efficacy.
|
|---|---|
|
Change in Serum Biomarkers - GM-CSF
Participant 1-Visit 0-Baseline
|
43.75 picograms/ml
|
|
Change in Serum Biomarkers - GM-CSF
Participant 1-Visit 1-Begin Low Dose Therapy
|
39.4 picograms/ml
|
|
Change in Serum Biomarkers - GM-CSF
Participant 1-Visit 2
|
43.2 picograms/ml
|
|
Change in Serum Biomarkers - GM-CSF
Participant 1-Visit 3
|
88.5 picograms/ml
|
|
Change in Serum Biomarkers - GM-CSF
Participant 1-Visit 4
|
11.5 picograms/ml
|
|
Change in Serum Biomarkers - GM-CSF
Participant 1-Visit 5-Begin High Dose Therapy
|
7.8 picograms/ml
|
|
Change in Serum Biomarkers - GM-CSF
Participant 1-Visit 6
|
7.8 picograms/ml
|
|
Change in Serum Biomarkers - GM-CSF
Participant 1-Visit 7
|
7.8 picograms/ml
|
|
Change in Serum Biomarkers - GM-CSF
Participant 1-Visit 8 - End of Therapy
|
7.8 picograms/ml
|
|
Change in Serum Biomarkers - GM-CSF
Participant 2-Baseline
|
26.8 picograms/ml
|
|
Change in Serum Biomarkers - GM-CSF
Participant 2-Begin Therapy
|
27.9 picograms/ml
|
|
Change in Serum Biomarkers - GM-CSF
Participant 2-Visit 2
|
24.8 picograms/ml
|
|
Change in Serum Biomarkers - GM-CSF
Participant 2-Visit 3
|
7.8 picograms/ml
|
|
Change in Serum Biomarkers - GM-CSF
Participant 2-Visit 4
|
7.8 picograms/ml
|
|
Change in Serum Biomarkers - GM-CSF
Participant 2-Visit 5-Begin High Dose Therapy
|
7.8 picograms/ml
|
|
Change in Serum Biomarkers - GM-CSF
Participant 2-Visit 6
|
7.8 picograms/ml
|
|
Change in Serum Biomarkers - GM-CSF
Participant 2-Visit 7
|
7.8 picograms/ml
|
|
Change in Serum Biomarkers - GM-CSF
Participant 2-Visit 8 - End of Therapy
|
7.8 picograms/ml
|
SECONDARY outcome
Timeframe: Baseline and monthly up to 7 monthsSurfactant protein D (SP-D) was measured via a commercial ELISA kit from Biovender.
Outcome measures
| Measure |
Inhaled Leukine (rhGM-CSF)
n=2 Participants
Inhaled recombinant human GM-CSF in individuals with Hereditary Pulmonary Alveolar Proteinosis (hPAP) due to partial dysfunction of the GM-CSF receptor
Leukine: Participants will receive inhaled rhGM-CSF (Sargramostim, Leukine) at the dose of 250 mcg one time per week for 12 weeks. Following an interim safety evaluation, participants may be entered into a second 12 week treatment period where participants will receive either 250 mcg or 500 mcg once weekly. At the end of any treatment period, participants will be followed for 12 additional weeks in the absence of inhaled rhGM-CSF to evaluate safety and efficacy.
|
|---|---|
|
Change in Serum Biomarkers - Surfactant Protein D
Participant 1-Visit 0-Baseline
|
796.2 nanograms/ml
|
|
Change in Serum Biomarkers - Surfactant Protein D
Participant 1-Visit 1-Begin Low Dose Therapy
|
619 nanograms/ml
|
|
Change in Serum Biomarkers - Surfactant Protein D
Participant 1-Visit 2
|
696.4 nanograms/ml
|
|
Change in Serum Biomarkers - Surfactant Protein D
Participant 1-Visit 3
|
589 nanograms/ml
|
|
Change in Serum Biomarkers - Surfactant Protein D
Participant 1-Visit 4
|
697.2 nanograms/ml
|
|
Change in Serum Biomarkers - Surfactant Protein D
Participant 1-Visit 5-Begin High Dose Therapy
|
536.9 nanograms/ml
|
|
Change in Serum Biomarkers - Surfactant Protein D
Participant 1-Visit 6
|
642.4 nanograms/ml
|
|
Change in Serum Biomarkers - Surfactant Protein D
Participant 1-Visit 7
|
495.9 nanograms/ml
|
|
Change in Serum Biomarkers - Surfactant Protein D
Participant 1-Visit 8 - End of Therapy
|
673.2 nanograms/ml
|
|
Change in Serum Biomarkers - Surfactant Protein D
Participant 2-Baseline
|
618.7 nanograms/ml
|
|
Change in Serum Biomarkers - Surfactant Protein D
Participant 2-Begin Therapy
|
469.6 nanograms/ml
|
|
Change in Serum Biomarkers - Surfactant Protein D
Participant 2-Visit 2
|
425.5 nanograms/ml
|
|
Change in Serum Biomarkers - Surfactant Protein D
Participant 2-Visit 3
|
381.3 nanograms/ml
|
|
Change in Serum Biomarkers - Surfactant Protein D
Participant 2-Visit 4
|
401.1 nanograms/ml
|
|
Change in Serum Biomarkers - Surfactant Protein D
Participant 2-Visit 5-Begin High Dose Therapy
|
298.2 nanograms/ml
|
|
Change in Serum Biomarkers - Surfactant Protein D
Participant 2-Visit 6
|
422 nanograms/ml
|
|
Change in Serum Biomarkers - Surfactant Protein D
Participant 2-Visit 7
|
456.8 nanograms/ml
|
|
Change in Serum Biomarkers - Surfactant Protein D
Participant 2-Visit 8 - End of Therapy
|
593 nanograms/ml
|
Adverse Events
Inhaled Leukine (rhGM-CSF)
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
Inhaled Leukine (rhGM-CSF)
n=2 participants at risk
Inhaled recombinant human GM-CSF in individuals with Hereditary Pulmonary Alveolar Proteinosis (hPAP) due to partial dysfunction of the GM-CSF receptor
Leukine: Participants will receive inhaled rhGM-CSF (Sargramostim, Leukine) at the dose of 250 mcg one time per week for 12 weeks. Following an interim safety evaluation, participants may be entered into a second 12 week treatment period where participants will receive either 250 mcg or 500 mcg once weekly. At the end of any treatment period, participants will be followed for 12 additional weeks in the absence of inhaled rhGM-CSF to evaluate safety and efficacy.
|
|---|---|
|
Respiratory, thoracic and mediastinal disorders
Upper Respiratory Tract Infection
|
100.0%
2/2 • Number of events 2 • Adverse events were collected from the time of consent until the of completion of the study, approximately 1 year.
|
|
General disorders
Noseblood
|
50.0%
1/2 • Number of events 1 • Adverse events were collected from the time of consent until the of completion of the study, approximately 1 year.
|
Additional Information
Dr. Bruce Trapnell
Cincinnati Children's Hospital Medical Center
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place